Guadalupe Gutierrez
Guadalupe Gutierrez has a total of 57 co-authors. Here are the top co-authors by number of shared publications:
- Daniel Haensel
Program in Epithelial Biology, Stanford University School of Medicine, Stanford, USA
2 shared publications - Kai Kessenbrock
Department of Biological Chemistry, University of California Irvine, Irvine, USA
2 shared publications - Xing Dai
School of Medicine, University of California 6 Department of Biological Chemistry Irvine, CA
2 shared publications - Alison P. Sanders
Department of Environmental and Occupational Health, School of Public Health, University of Pittsburgh, Pittsburgh, USA
1 shared publication - Andrea Musa
Pfizer, Inc , New York, New York
1 shared publication - Anthony Letai
Dana-Farber Cancer Institute, Boston, USA
1 shared publication
Latest Publications
- Open Access
- 24 August 2026
- Published by American Association for Cancer Research (AACR) in Molecular Cancer Therapeutics
- p. OF1-OF11
PF-08046876, a Differentiated Integrin Beta-6 Antibody–Drug Conjugate Delivering a Potent Camptothecin Payload Optimized for Bystander Effect and Reduced Drug Efflux
Integrins represent a large family of cell surface receptors that exist as heterodimers with essential roles in key biological processes such as cellular adhesion, motility, and cytokinesis. Among them, integrin beta-6 (IB6), which exclusively dimerizes with integrin alpha-v, has emerged as a clinically relevant target due to its restricted expression in normal adult epithelial tissues and elevated levels in solid tumors. High expression of IB6 is correlated with poor prognosis across multiple solid tumor types. PF-08046876 is an investigational antibody–drug conjugate consisting of the anti-IB6 mAb conjugated to a camptothecin-class topoisomerase I (TOP1) inhibitor, 7-aminomethyl-10,11-methylenedioxycamptothecin (AMDCPT), using a traceless enzyme-cleavable glucuronide linker. The AMDCPT payload has been optimized for differentiation from other TOP1 inhibitors, with improved potency, enhanced bystander activity, and reduced susceptibility to multidrug resistance efflux mechanisms. PF-08046876 leverages the same antibody backbone from sigvotatug vedotin and binds IB6 without cross-reactivity to other alpha-v integrin complexes. In preclinical studies, PF-08046876 has demonstrated significant antitumor activity both in vitro and in vivo across multiple tumor models with IB6 expression, including non–small cell lung, head and neck squamous cell, urothelial, pancreatic, and esophageal carcinomas. These findings support further clinical development of PF-08046876 as a promising therapeutic candidate for the treatment of IB6-expressing solid tumors.
- 24 August 2026
- Published by American Association for Cancer Research (AACR) in Molecular Cancer Therapeutics
- p. OF1-OF11
Open AccessPF-08046876, a Differentiated Integrin Beta-6 Antibody–Drug Conjugate Delivering a Potent Camptothecin Payload Optimized for Bystander Effect and Reduced Drug Efflux
Integrins represent a large family of cell surface receptors that exist as heterodimers with essential roles in key biological processes such as cellular adhesion, motility, and cytokinesis. Among them, integrin beta-6 (IB6), which exclusively dimerizes with integrin alpha-v, has emerged as a clinically relevant target due to its restricted expression in normal adult epithelial tissues and elevated levels in solid tumors. High expression of IB6 is correlated with poor prognosis across multiple solid tumor types. PF-08046876 is an investigational antibody–drug conjugate consisting of the anti-IB6 mAb conjugated to a camptothecin-class topoisomerase I (TOP1) inhibitor, 7-aminomethyl-10,11-methylenedioxycamptothecin (AMDCPT), using a traceless enzyme-cleavable glucuronide linker. The AMDCPT payload has been optimized for differentiation from other TOP1 inhibitors, with improved potency, enhanced bystander activity, and reduced susceptibility to multidrug resistance efflux mechanisms. PF-08046876 leverages the same antibody backbone from sigvotatug vedotin and binds IB6 without cross-reactivity to other alpha-v integrin complexes. In preclinical studies, PF-08046876 has demonstrated significant antitumor activity both in vitro and in vivo across multiple tumor models with IB6 expression, including non–small cell lung, head and neck squamous cell, urothelial, pancreatic, and esophageal carcinomas. These findings support further clinical development of PF-08046876 as a promising therapeutic candidate for the treatment of IB6-expressing solid tumors.
- Open Access
- 17 September 2023
- Published by Environmental Health Perspectives in ISEE Conference Abstracts
- Vol. 2023 (1)
Associations of Exposure to Urinary Metals with Kidney Injury Biomarkers among Pre-adolescent Children: A Cross-Sectional Study
- 17 September 2023
- Published by Environmental Health Perspectives in ISEE Conference Abstracts
- Vol. 2023 (1)
Open AccessAssociations of Exposure to Urinary Metals with Kidney Injury Biomarkers among Pre-adolescent Children: A Cross-Sectional Study
- 14 December 2020
- Published by Elsevier in Journal of Investigative Dermatology
- Vol. 141 (6) , 1542-1552
OVOL1 Regulates Psoriasis-Like Skin Inflammation and Epidermal Hyperplasia
- 14 December 2020
- Published by Elsevier in Journal of Investigative Dermatology
- Vol. 141 (6) , 1542-1552
OVOL1 Regulates Psoriasis-Like Skin Inflammation and Epidermal Hyperplasia
- Open Access
- 1 October 2020
- Published by Elsevier in Cell Reports
- Vol. 33 (3) , 108273
Integrated Single-Cell Transcriptomics and Chromatin Accessibility Analysis Reveals Regulators of Mammary Epithelial Cell Identity
- 1 October 2020
- Published by Elsevier in Cell Reports
- Vol. 33 (3) , 108273
Open AccessIntegrated Single-Cell Transcriptomics and Chromatin Accessibility Analysis Reveals Regulators of Mammary Epithelial Cell Identity
- Open Access
- 18 January 2019
- Published by IOP Publishing in Physical Biology
- Vol. 16 (2) , 021001
Intermediate cell states in epithelial-to-mesenchymal transition
The transition of epithelial cells into a mesenchymal state (epithelial-to-mesenchymal transition or EMT) is a highly dynamic process implicated in various biological processes. During EMT, cells do not necessarily exist in 'pure' epithelial or mesenchymal states. There are cells with mixed (or hybrid) features of the two, which are termed as the intermediate cell states (ICSs). While the exact functions of ICS remain elusive, together with EMT it appears to play important roles in embryogenesis, tissue development, and pathological processes such as cancer metastasis. Recent single cell experiments and advanced mathematical modeling have improved our capability in identifying ICS and provided a better understanding of ICS in development and disease. Here, we review the recent findings related to the ICS in/or EMT and highlight the challenges in the identification and functional characterization of ICS.
- 18 January 2019
- Published by IOP Publishing in Physical Biology
- Vol. 16 (2) , 021001
Open AccessIntermediate cell states in epithelial-to-mesenchymal transition
The transition of epithelial cells into a mesenchymal state (epithelial-to-mesenchymal transition or EMT) is a highly dynamic process implicated in various biological processes. During EMT, cells do not necessarily exist in 'pure' epithelial or mesenchymal states. There are cells with mixed (or hybrid) features of the two, which are termed as the intermediate cell states (ICSs). While the exact functions of ICS remain elusive, together with EMT it appears to play important roles in embryogenesis, tissue development, and pathological processes such as cancer metastasis. Recent single cell experiments and advanced mathematical modeling have improved our capability in identifying ICS and provided a better understanding of ICS in development and disease. Here, we review the recent findings related to the ICS in/or EMT and highlight the challenges in the identification and functional characterization of ICS.
- 1 July 2014
- Published by Elsevier in European Journal of Cancer
- Vol. 50, S172
715: BCL-2 dependence in T-cell leukemia is defined by the maturation stage of the clone of origin
- 1 July 2014
- Published by Elsevier in European Journal of Cancer
- Vol. 50, S172
715: BCL-2 dependence in T-cell leukemia is defined by the maturation stage of the clone of origin